Targeted lung cancer mrna therapy with lipo-polymeric nanoparticles

Overview

RJH Biosciences is pioneering a novel approach to lung cancer therapy through the use of targeted mRNA delivery systems. Our proprietary lipo-polymeric nanoparticles are designed to deliver a combination of therapeutic mRNA sequences directly to lung cancer cells. This method aims to induce apoptosis in cancer cells by leveraging the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and enhancing its effects through the restoration of the wild-type p53 gene and the knockout of the survivin gene, which is known to inhibit apoptosis.

Technical specifications

Key features:

• Targeted Delivery: Lipo-polymeric nanoparticles efficiently encapsulate and deliver approximately 10kb of RNA, ensuring precise targeting to lung cancer cells.
• Combinatorial Therapy: Utilizes TRAIL mRNA, p53 tumor suppressor gene, and survivin sgRNA/Cas9 mRNA for a synergistic pro-apoptotic effect.
• Real-time Monitoring: Incorporation of luciferase (Luc) mRNA allows for real-time tracking of therapeutic efficacy.
• Demonstrated Efficacy: Proven in vivo tumor reduction in lung and breast cancer models, with in vitro inhibition of cell growth through Cas9-mediated survivin knockout.

Technology readiness level

Our lipo-polymeric nanoparticle technology is at TRL 5, having demonstrated proof-of-concept in preclinical models. We are currently seeking partners for further preclinical validation and to support the development of mRNA therapeutics through in vivo model access and comprehensive immune profiling.